3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
49
Carcinoma, Renal Cell
30
Neoplasm Metastasis
18
Neoplasms
15
Kidney Neoplasms
14
Neuroendocrine Tumors
11
Carcinoma, Neuroendocrine
9
Prostatic Neoplasms
7
Melanoma
7
Triple Negative Breast Neoplasms
6
Thyroid Neoplasms
6
Sarcoma
6
Meningioma
6
Lymphoma
6
Glioma
6
Endometrial Neoplasms
6
Tuberous Sclerosis
5
Stomach Neoplasms
5
Recurrence
5
Lymphoma, Mantle-Cell
5
Head and Neck Neoplasms
5
Colorectal Neoplasms
5
Carcinoma, Hepatocellular
5
Carcinoma
5
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Lymphoma, Large B-Cell, Diffuse
4
Liver Neoplasms
4
Carcinoma, Islet Cell
4
Astrocytoma
4
Interventions
pembrolizumab
3
apatinib
3
Magnetic Resonance Spectroscopy
3
lenvatinib
2
Specimen Handling
2
Nivolumab
2
Imatinib Mesylate
2
Epirubicin
2
Cisplatin
2
Carboplatin
2
Axitinib
2
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
regorafenib
1
gallium 68 PSMA-11
1
enfortumab vedotin
1
cabozantinib
1
avelumab
1
anlotinib
1
amivantamab
1
Tretinoin
1
Sunitinib
1
Radiation
1
Pemetrexed
1
Nelfinavir
1
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
1
Lutetium-177
1
Lutetium
1
Ipilimumab
1
Glutamate Carboxypeptidase II
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Carcinoma, Adenoid Cystic
×
Everolimus
×
Clear all
NCT01152840
2015-05-20
ACCRAD001
Seoul National University Hospital
Phase 2
Completed
33 enrolled